Single-agent pembrolizumab is recommended for stage IV non-squamous cell carcinoma (non-SCC) and squamous cell carcinoma (SCC) with high PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50%) and a PS of 0 to 1. Here, CD274 is linked to neoplasm.